Hubbry Logo
AmatoxinAmatoxinMain
Open search
Amatoxin
Community hub
Amatoxin
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Amatoxin
Amatoxin
Amatoxin
View on Wikipedia
from Wikipedia

Amatoxins are a subgroup of at least nine related cyclic peptide toxins found in three genera of deadly poisonous mushrooms (Amanita, Galerina and Lepiota) and one species of the genus Pholiotina.[1] Amatoxins are very potent, as little as half a mushroom cap can cause severe liver injury if swallowed.

Structure

[edit]
The backbone structure (black) is the same in all the amatoxins and five variable groups (red) determine the specific compound.

The compounds have a similar structure, that of eight amino-acid residues arranged in a conserved macrobicyclic motif (an overall pentacyclic structure when counting the rings inherent in the proline and tryptophan-derived residues); they were isolated in 1941 by Heinrich O. Wieland and Rudolf Hallermayer.[2] All amatoxins are cyclic peptides that are synthesized as 35-amino-acid proproteins, from which the final eight amino acids are cleaved by a prolyl oligopeptidase.[3] The schematic amino acid sequence of amatoxins is Ile-Trp-Gly-Ile-Gly-Cys-Asn-Pro with cross-linking between Trp and Cys via the sulfoxide (S=O) moiety and hydroxylation in variants of the molecule; enzymes for these processings steps remain unknown.

There are currently ten named amatoxins:[4]

Name R1 R2 R3 R4 R5
α-Amanitin OH OH NH2 OH OH
β-Amanitin OH OH OH OH OH
γ-Amanitin OH H NH2 OH OH
ε-Amanitin OH H OH OH OH
Amanullin H H NH2 OH OH
Amanullinic acid H H OH OH OH
Amaninamide OH OH NH2 H OH
Amanin OH OH OH H OH
Proamanullin H H NH2 OH H

δ-Amanitin has been reported, but its chemical structure has not been determined.

Family relations

[edit]
Amanitin/phalloidin precursor
Identifiers
SymbolAmanitin/phalloidin
InterProIPR027582

Amanitin is very closely related to phalloidins, which are bicyclic 7-residue toxins. They both are part of the MSDIN protein family, so named after the highly conserved 5-amino-acid sequence in the preproteins. A 2014 research study determined that there exists a significant number of uncharacterized MSDIN sequences in Amanita genomes.[5]

Mechanism

[edit]

Amatoxins are potent and selective inhibitors of RNA polymerase II (RNA Pol II), a vital enzyme in the synthesis of messenger RNA (mRNA), microRNA, and small nuclear RNA (snRNA). Without mRNA, which is the template for protein synthesis, cell metabolism stops and apoptosis ensues.[6] The RNA polymerase of Amanita phalloides has mutations that make it insensitive to the effects of amatoxins; thus, the mushroom does not poison itself.[7]

Amatoxins are able to travel through the bloodstream to reach the organs in the body. While these compounds can damage many organs, damage to the liver and heart result in fatalities. At the molecular level, amatoxins cause damage to cells of these organs by causing perforations in the plasma membranes resulting in misplaced organelles that are normally in the cytoplasm to be found in the extracellular matrix.[8] beta-Amanitin is also an inhibitor of eukaryotic RNA polymerase II and RNA polymerase III, and as a result, mammalian protein synthesis. It has not been found to inhibit RNA polymerase I or bacterial RNA polymerase.[9] Because it inactivates the RNA polymerases, the liver is unable to repair damage and the cells of the liver die off quickly.[10]

Ribbon diagram of RNA polymerase II molecule showing central binding site of alpha-amanitin molecule
α-Amanitin (red) bound to RNA polymerase II from Saccharomyces cerevisiae (brewer's yeast). From PDB: 1K83​.[11]

Alpha-amanitin (α-Amanitin) primarily affects the bridge helix of the RNA pol II complex, a highly conserved domain 35 amino acids long. At the N-terminus and the C-terminus of this region there are hinge structures that undergo significant conformational changes throughout the nucleotide addition cycle, and are essential for its progression.[12] One of the many roles of the bridge helix is facilitating the translocation of DNA.[13] Alpha-amanitin binds to the bridge helix of the RNA Pol II complex and it also binds to part of the complex that is adjacent to the bridge helix, while it is in one specific conformation. This binding locks the bridge helix into place, dramatically slowing its movement in translocating the DNA.[11] The rate of pol II translocation of DNA is reduced from several thousand to a few nucleotides per minute.[14][15]

Symptoms of exposure

[edit]

Upon exposure to amatoxins, the liver is the principal organ affected as it is the organ which is first encountered after absorption in the gastrointestinal tract. There is no evidence that amatoxins are absorbed through skin. One study done on mice shows that alpha-Amanitin is not absorbed through skin and therefore cannot have any toxic effects.[16] More specifically, exposure to amatoxins may cause irritation of the respiratory tract, headache, dizziness, nausea, shortness of breath, coughing, insomnia, diarrhea, gastrointestinal disturbances, back pain, urinary frequency, liver and kidney damage, or death if ingested or inhaled. For β-amanitin, there has been no full toxicological study. However, safety data sheets indicate that if it comes in contact with skin, it may cause irritation, burns, redness, severe pain, and could be absorbed through the skin, causing similar effects to exposure via inhalation and ingestion. Contact with the eyes may result in irritation, corneal burns, and eye damage.[17] Persons with pre-existing skin, eye, or central nervous systems disorders, impaired liver, kidney, or pulmonary function may be more susceptible to the effects of this substance.

The estimated minimum lethal dose is 0.1 mg/kg or 7  to 10 milligrams of toxin in adults. Their swift intestinal absorption coupled with their thermostability leads to rapid development of toxic effects in a relatively short period of time. The most severe effects are toxic hepatitis with centrolobular necrosis and hepatic steatosis, as well as acute tubulointerstitial nephropathy, which altogether induce severe liver failure and kidney failure.

Treatment

[edit]

There are many anecdotal and partially-studied treatments in use worldwide. One study in mice showed null results for all studied treatments. Treatments showing no discernable value included N-acetylcysteine, benzylpenicillin, cimetidine, thioctic acid, and silybin.[18]

Treatment involves high-dose penicillin as well as supportive care in cases of hepatic and renal injury. Silibinin, a product found in milk thistle, is a potential antidote to amatoxin poisoning, although more data needs to be collected. Cautious attention is given to maintaining hemodynamic stability, although if hepatorenal syndrome has developed the prognosis is guarded at best.[19]

Detection

[edit]

Presence of amatoxins in mushroom samples may be detected by the Meixner test (also known as the Wieland test). The amatoxins may be quantitated in plasma or urine using chromatographic techniques to confirm a diagnosis of poisoning in hospitalized patients and in postmortem tissues to aid in a medicolegal investigation of a suspected fatal overdosage.[20]

In 2020, a monoclonal antibody-based lateral flow immunoassay has been developed that can quickly and selectively detect amatoxins.[21][22] This test sensitively detects alpha-amanitin and gamma-amanitin (clearly detects 10 ng/mL), and exhibits slightly less detection for beta-amanitin (0.5% cross-reactivity; 2000 ng/mL). Although this test cross-reacts with phallotoxins at 0.005% (200,000 ng/mL), the phallotoxins would not interfere in urine sampling and there are very rare instances where a mushroom produces phallotoxins without producing amatoxins.

Studies

[edit]

In a 2013 study on the toxin concentration in Amanita phalloides, all parts of the mushroom were found to contain amatoxins and it was determined that the highest concentrations were found in the gills and cap with the lowest levels in the spores and mycelium.[23] An additional study published in 2013 by many of the same authors found no difference in the ITS sequence of Amanita phalloides var. alba but did find different concentrations of toxins.[24] The gills and cap of Amanita phalloides var. alba also contained the highest level with very low levels noted in the spores, volva and stipe however in this variant the spores had a higher concentration of all toxins besides gamma amanitin than was found in Amanita phalloides. The spores of Amanita phalloides var. alba contained 0.89 mg/g of alpha-amanitin, 0.48 mg/g of beta-amanitin and 0.001 mg/g gamma-amanitin in contrast to the 2.46, 1.94 and 0.36 mg/g found in the gills and the 2.40, 1.75 and 0.27 mg/g found in the cap. The concentration found in the gills, cap, stipe and volva of Amanita phalloides var. alba is lower than in Amanita phalloides however the spores were shown to contain a higher concentration.[24] In both studies six mushrooms were spore printed, dried and tested with the toxin level in the whole mushroom being derived from testing one half of the whole mushroom cut down the middle, the other half was divided into cap, gill, stipe and volva sections to test individually with the parts ground into a powder and tested as 1gram samples.[23][24] In 2010, a study on Amanita bisporigera, the destroying angel, determined that the concentrations of toxins in the spores were also lower than the levels found in the cap or stipe.[25]

Toxin concentration in Amanita phalloides (mg/g)[23]
Toxin Cap Gills Stipe Volva Spores Whole dry mushroom Whole fresh mushroom Mycelium
Alpha-amanitin 2.95 3.39 2.36 1.03 0.087 2.80 0.33 0.024
Beta-amanitin 2.53 2.95 1.75 0.64 0.048 2.38 0.28 0.01
Gamma-amanitin 0.62 0.66 0.5 0.25 0.18 0.6 0.07 0.24
Phallacidin 2.27 2.06 2.04 1.88 0.055 2.12 0.25 0.42
Phalloidin 1.40 1.38 1.18 1.25 0.018 1.32 0.15 0.01
Toxin concentration in Amanita phalloides var. alba (mg/g)[24]
Toxin Cap Gills Stipe Volva Spores Whole dry mushroom Whole fresh mushroom
Alpha-amanitin 2.40 2.46 1.52 0.56 0.89 2.14 0.21
Beta-amanitin 1.75 1.94 1.00 0.36 0.48 1.71 0.16
Gamma-amanitin 0.27 0.36 0.21 0.07 0.001 0.31 0.03
Phallacidin 1.64 2.26 2.06 2.08 0.99 2.10 0.20
Phalloidin 0.87 1.30 1.13 1.34 0.12 1.09 0.10
Toxin concentration in Amanita bisporigera (mg/g)[25]
Toxin Cap Stipe Spores
Alpha-amanitin 1.70 ± 0.68 1.70 ± 0.45 0.30 ± 0.04
Phallacidin 2.71 ± 0.65 1.66 ± 0.40 0.02 ± 0.01
Phalloidin 11.98 ± 1.66 11.15 ± 2.43 0.00 ± 0.05

Amatoxins are extremely toxic to humans with Amanita phalloides and its variants making up many of the cases of fatal toxicity after consumption.These toxins have high heat stability and this property combined with their solubility in water make them exceptionally toxic as they are not destroyed by cooking or drying.[26] In addition, amatoxins are resistant to enzyme and acid degradation, and therefore when ingested they are not inactivated in the gastrointestinal tract.[26] A fatal case was reported after consuming A. phalloides that had been frozen for 7–8 months, thus demonstrating that these compounds are also resistant to the freeze/thawing processes.[26] Additionally, amatoxins decompose very slowly when stored in open, aqueous solutions or following prolonged exposure to sun or neon light.[26]

In 2015, a case study was conducted on a patient who cooked and consumed just the caps from two Amanita phalloides mushrooms and was subsequently admitted to hospital a day later. The subject was a 61-year-old man with a body weight of 67 kg who was presenting with fatigue, abdominal pain, nausea, vomiting and diarrhea. Mushrooms were collected from the same region and shown to the patient in order to confirm that these were what he had eaten and two mushrooms of approximately the same size and level of maturity were selected for study.[27] Previous studies have demonstrated that younger mushrooms can contain a higher concentration of toxins than is found in mature specimens.[28] The combined weight of the caps of these two mushrooms was 43.4g fresh or 4.3g when dry and when tested were found to contain a total of 21.3 mg of amatoxin distributed as 11.9 mg alpha-amanitin, 8.4 mg beta-amanitin and 1 mg gamma-amanitin. Analysis of the patient's urine after 4 days of treatment in hospital showed a concentration of 2.7 ng/ml alpha-amanitin and 1.25 ng/ml beta-amanitin with no gamma-amanitin detected. The patient survived and was discharged after 9 days of treatment with follow up tests showing no signs of liver damage but based on this case it was estimated that an oral dose of 0.32 mg amatoxin per kg of body mass could be lethal with an approximate lethal dose of alpha-amanitin being 0.2 mg/kg when taken orally. It was estimated that consuming more than 50g of fresh Amanita phalloides, roughly 2 medium-sized mushrooms could be deadly. Clinical tests showed that the amount consumed by the patient remained below the hypothetical lethal dose, which the study notes probably varies depending on patient health, predisposition to liver damage and regional variation in toxin concentrations.[27]

Anecdotes have been repeated in field guides that claim foragers have fallen ill from spores alone after collecting toxic Amanita species in the same basket, unwittingly leaving their spores to collect on the harvest before the toxic ones were discarded. This subject however has not been researched and studies make no claims one way or the other as to the possibility of poisoning from spores alone. Given that the concentration of toxins found in the spores is lower than that of the cap, it would require the consumption of a substantial mass of spores, in excess of the weight of the mushroom caps themselves, in order to reach a fatal dose.

Mushroom species

[edit]

Amatoxin-containing mushroom species from the genera Amanita, Galerina and Lepiota.[29][30]

Amanita species Galerina species Lepiota species
Amanita phalloides Galerina badipes Lepiota brunneoincarnata
Amanita bisporigera Galerina beinrothii Lepiota brunneolilacea
Amanita decipiens Galerina fasciculata Lepiota castanea
Amanita hygroscopica Galerina helvoliceps Lepiota clypeolaria
Amanita ocreata Galerina marginata Lepiota clypeolarioides
Amanita suballiacea Galerina sulciceps Lepiota felina
Amanita tenuifolia Galerina unicolor Lepiota fulvella
Amanita verna Galerina venenata Lepiota fuscovinacea
Amanita virosa Lepiota griseovirens
Lepiota heimii
Lepiota helveoloides
Lepiota kuehneri
Lepiota langei
Lepiota lilacea
Lepiota locanensis
Lepiota ochraceofulva
Lepiota pseudohelveola
Lepiota pseudolilacea
Lepiota rufescens
Lepiota subincarnata
Lepiota xanthophylla

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Amatoxin

View on Grokipedia
from Grokipedia
Amatoxins are a family of potent, heat-stable bicyclic octapeptide toxins produced by certain poisonous mushrooms, primarily in the genera Amanita, Galerina, and Lepiota, and are responsible for approximately 95% of fatal mushroom poisonings worldwide. These toxins, including the most lethal α-amanitin, inhibit RNA polymerase II, disrupting mRNA transcription and protein synthesis in cells, particularly hepatocytes, leading to acute liver failure and potentially death within days of ingestion. With a lethal dose as low as 0.1 mg/kg body weight in humans—equivalent to about 7-8 mg for an average adult—amatoxins are among the most toxic naturally occurring substances, causing symptoms in distinct phases: initial gastrointestinal distress (nausea, vomiting, diarrhea) 6-12 hours post-ingestion, followed by a latent period and then fulminant hepatic and renal failure. Chemically, amatoxins are cyclic peptides with a molecular weight of around 900 Da, featuring unique amino acids such as dihydroxy-isoleucine, hydroxy-tryptophan, and hydroxy-proline, along with a characteristic transannular thioether bridge that contributes to their stability. They exhibit high water solubility and resistance to heat (up to 250-280°C), enzymatic degradation, and acidic conditions, making them persistent even when mushrooms are cooked or processed. The primary producer, Amanita phalloides (death cap mushroom), contains the highest concentrations, up to 2-3 mg/g of dry tissue, with α-amanitin being the most abundant and toxic variant, binding irreversibly to RNA polymerase II via hydrogen bonding to its bridgehead amide. Other notable amatoxins include β-amanitin, γ-amanitin, and ε-amanitin, each varying slightly in potency but sharing the core bicyclic octapeptide structure derived from a tryptophan residue with sulfur substitution. The toxicity of amatoxins primarily targets the liver, where they are actively transported into hepatocytes via the organic anion-transporting polypeptide 1B3 (OATP1B3), inducing , , and through halted protein synthesis and synergy with pro-inflammatory cytokines like TNF-α. Renal involvement occurs secondarily due to reabsorption and direct tubular damage, exacerbating multi-organ failure if untreated. relies on clinical history, elevated liver enzymes, and detection of amatoxins in serum or via methods like HPLC or , as symptoms mimic other hepatotoxins. Treatment is supportive, including activated for , N-acetylcysteine for effects, high-dose penicillin G or to competitively inhibit uptake, and extracorporeal procedures like in severe cases; remains the definitive option for fulminant failure, with rates improving to over 50% with early intervention. Despite these advances, amatoxin poisonings continue to pose a risk, particularly in regions with high wild consumption.

Chemical Characteristics

Molecular Structure

Amatoxins are bicyclic octapeptides composed of eight L-amino acids arranged in a rigid cyclic framework, featuring a transannular thioether bridge—known as tryptathionine—connecting the side chains of a residue and a residue, which forms the characteristic inner loop structure. This bicyclic architecture is further stabilized by intramolecular hydrogen bonds between amide groups and hydrophobic interactions among the backbone and side chains, conferring exceptional conformational rigidity essential for their . The primary amatoxin, , has the molecular formula \ceC39H54N10O14S\ce{C39H54N10O14S} and a molecular weight of 918.97 Da. Its peptide sequence is , cyclized via a between the and , with the thioether bridge linking the to the 2-position of the ring. Key structural modifications include a hydroxyl group at the 6'-position of the , a 4,5-dihydroxy substitution on the at position 1, and a trans-4-hydroxy group on the , contributing to the molecule's polarity and hydrogen-bonding potential. The form of the thioether bridge in some amatoxins enhances oxidative stability, while the overall rigid bicyclic system ensures resistance to conformational changes under physiological conditions. These structural elements impart unique physicochemical properties to amatoxins, including high thermal and that persists in acidic environments such as the gastric , allowing intact absorption without degradation. The presence of multiple hydroxyl groups results in low in non-polar solvents like or , but good in polar media such as and , facilitating . Additionally, the cyclic and cross-linked nature renders amatoxins highly resistant to proteolytic enzymes, preventing breakdown by peptidases in the digestive tract or bloodstream.

Variants and Family Relations

Amatoxins encompass a group of closely related bicyclic octapeptides, with the primary variants including , β-amanitin, γ-amanitin, and ε-amanitin. α-Amanitin is the most potent and abundant in toxic mushrooms, followed by β-amanitin, while γ- and ε-amanitin occur in lower concentrations and exhibit reduced toxicity. These variants share a core structure featuring a tryptathionine cross-bridge between and residues, along with unusual such as 4-hydroxyproline and dihydroxyisoleucine. Structural differences among the variants primarily arise from variations in , oxidation states, and substitutions. For instance, β-amanitin lacks the 6'-hydroxyl group on the unit present in α-amanitin and features a bridge instead of the , which contributes to its lower binding affinity to and thus diminished potency. In contrast, α-amanitin possesses the 6'-hydroxyl and a bridge, while γ-amanitin has the 6'-hydroxyl but a bridge and an unmodified at position 1, resulting in slightly lower toxicity than α-amanitin. ε-Amanitin includes additional carboxyl modifications, making it the least potent among the main variants. These modifications directly influence potency, with the order generally following α > β > γ > ε. Amatoxins belong to a broader family of bicyclic peptide toxins produced by fungi in the genera , , and , which also includes phallotoxins as related but distinct cyclic heptapeptides. Phallotoxins, such as , share the tryptathionine bridge but differ in ring size and lack the inhibition characteristic of amatoxins; instead, they bind to filaments, stabilizing F-actin without overlapping in transcriptional blockade. This distinction underscores their complementary roles in fungal defense, with amatoxins targeting processes and phallotoxins affecting cytoskeletal dynamics. Relative toxicities of amatoxin variants are linked to these structural motifs, with exhibiting an oral LD50 of approximately 0.1–0.3 mg/kg in mice, reflecting its strong inhibition of . β-Amanitin has a higher LD50 (around 0.6–1.2 mg/kg), due to weaker binding, while γ- and ε-amanitin show even greater thresholds, emphasizing how and oxidation enhance lethality. Phallotoxins are generally 10–20 times less toxic than amatoxins , as they are poorly absorbed and rapidly degraded. The conserved tryptathionine motif and ribosomally encoded precursor genes (featuring the MSDIN sequence) across amatoxins and phallotoxins suggest a common evolutionary ancestry within fungal pathways. These genes likely originated from horizontal transfer events among and , enabling diversification through gene family expansions in toxin-producing genera like , where up to 40 MSDIN variants facilitate structural variety. This evolutionary adaptation highlights their role as specialized defenses against herbivores and competitors in fungal .

Natural Occurrence

Mushroom Species

Amatoxins are primarily produced by certain species within the genera Amanita, Galerina, Lepiota, and , with (death cap) being the most notorious due to its high toxin concentrations, reaching up to 2.95 mg/g dry weight in mature fruiting bodies. Other key producers include (destroying angel, 3.4–4.5 mg/g total amatoxins), (2–3 mg/g total), and (deadly webcap, 0.5–2 mg/g), all of which pose significant risks due to their lethality even in small quantities. Reported concentrations occur in species like (1–2 mg/g total) and Conocybe filaris (variable in some specimens, up to 0.3 mg/g). Toxin profiles vary by species, but in A. phalloides, α-amanitin typically constitutes 40–50% of total amatoxins (e.g., 66–75% in some samples), followed by β-amanitin (19–49%) and γ-amanitin (3–11%), with the highest levels often in the gills (up to 4.8 mg/g dry weight). In contrast, G. marginata and Lepiota species generally have lower proportions of α-amanitin (around 30–50%) and variable overall toxin loads, making them less potent but still hazardous in larger ingestions. These mushrooms are widely distributed in temperate regions of Europe, , and , where they form ectomycorrhizal associations with trees like and beeches in damp, shaded woodlands. A. phalloides, native to , has spread invasively to since the 19th century via imported oak trees, establishing populations in urban areas like and . Amatoxins likely serve an ecological role as chemical defenses against herbivores, , and microbial competitors, with concentrations peaking during periods of vigorous growth in autumn fruiting bodies. Misidentification poses a major risk, as amatoxin-containing species like A. phalloides and A. bisporigera are often confused with edible mushrooms such as the straw mushroom (Volvariella volvacea) or the smooth parasol (Lepiota naucina), leading to accidental poisonings among foragers. Color variations and habitat overlap exacerbate these errors, particularly in regions with introduced populations.

Biosynthesis

Amatoxins are biosynthesized in certain Basidiomycete fungi, primarily species of the genus Amanita, through a ribosomal peptide synthesis pathway involving a multigene family rather than non-ribosomal peptide synthetases. The genetic basis resides in the MSDIN gene family, which encodes precursor propeptides of 34–37 amino acids, with AMA1 specifically directing the synthesis of the α-amanitin precursor in Amanita bisporigera. These genes are scattered across the genome, spanning distances of up to 31.97 Mbp, rather than forming a tight operon, though functional coordination occurs through co-expression during fungal development. Recent genomic analyses, including RNA-seq data from A. bisporigera, have identified 8–10 core genes in the pathway, confirming expansions in the MSDIN family (19–40 copies) that enable high toxin yields. The biosynthetic pathway begins with ribosomal of the MSDIN-encoded propeptide, featuring a leader sequence, a core region (7–10 ), and a recognition motif for processing. Prolyl oligopeptidase B (POPB), encoded by a dedicated , then cleaves the leader and catalyzes macrocyclization via and transpeptidation at residues, forming the initial scaffold. Subsequent modifications include cysteine S-methylation and rearrangement to form the tryptathionine bridge, followed by hydroxylation at specific residues (e.g., prolines and ) by Amanita-specific enzymes such as AbP450-1, -2, and -3. Final maturation involves oxidation of the tryptathionine by flavin monooxygenase 1 (FMO1), with disruption of FMO1 abolishing α-amanitin production. Methyltransferases like MSD1 contribute to early modifications, while isomerases ensure proper in the bicyclic structure. The amatoxin synthase complex, comprising POPB, P450s, FMO1, and associated methyltransferases, operates in a coordinated manner, with expression peaking during the fruiting body maturation stage in response to developmental cues. Evolutionary studies suggest the toxin gene cluster arose via horizontal gene transfer from an ancestral donor to Basidiomycetes, evidenced by monophyletic clades of POPB incongruent with species phylogenies and low substitution rates indicating selective retention. In Amanita, lineage-specific expansions of MSDIN genes and recruitment of novel P450s have amplified toxin diversity and potency compared to relatives like Galerina.

Toxicological Mechanism

Molecular Interaction

Amatoxins exert their toxicity by specifically targeting (RNAP II), the enzyme responsible for transcribing in eukaryotic cells. The primary is located in the bridge helix region, also referred to as the Wahle domain, within the funnel-shaped cleft of the enzyme formed by the Rpb1 and Rpb2 subunits. , the most potent variant, binds with exceptionally high affinity, characterized by a (K_d) of approximately 3 nM, enabling effective inhibition at subnanomolar concentrations. The binding mechanism involves multiple non-covalent interactions that position the toxin deeply within the active site. Key hydrogen bonds form between the toxin's hydroxyproline residue and Glu822 of RNAP II, as well as indirect bonds involving Gln768 and His816; additional van der Waals contacts and hydrophobic interactions occur, including the insertion of the isoleucine-6 side chain into a hydrophobic pocket near the bridge helix. These interactions cause steric blockage, preventing the translocation of DNA and RNA necessary for elongation while still allowing nucleotide entry and initial phosphodiester bond formation. The inhibition is functionally irreversible due to the toxin's tight grip (slow dissociation rate), though it is not covalently linked, and it competes with nucleotide triphosphate substrates during the elongation phase without disrupting transcription initiation. Amatoxins demonstrate high specificity for eukaryotic RNAP II, with little to no effect on bacterial RNA polymerases or mitochondrial polymerases at physiologically relevant doses, owing to structural differences in the binding pocket across these enzyme types. Among amatoxin variants, exhibits the greatest potency, inhibiting mRNA synthesis by over 90% at low nanomolar concentrations, while variants like β-amanitin require higher doses for comparable effects due to subtle differences in their structures. Structural insights into this interaction have been elucidated through , notably in the 2002 study by Bushnell et al., which resolved the –RNAP II complex at 2.8 Å resolution (PDB ID: 1K83). This work shows the toxin nestled snugly in the cleft, confirming the molecular basis for its inhibitory action and highlighting how in the bridge can confer resistance in certain species.

Cellular and Physiological Effects

Amatoxins induce transcriptional arrest by inhibiting , preventing mRNA synthesis and leading to rapid depletion of existing mRNA transcripts, whose half-lives in s and enterocytes typically range from 2 to 10 hours. This depletion swiftly halts protein synthesis in these sensitive cells, as demonstrated in hepatocyte cultures where incorporation of labeled into proteins decreases by over 90% within hours of exposure. The resulting lack of essential proteins disrupts cellular , particularly in high-transcription-rate tissues like the liver and . Cell death ensues through multiple pathways, with predominating in moderate exposures via activation, which upregulates pro-apoptotic factors like Bax and triggers cascades, including caspase-3. This mitochondrial-mediated is evident in human hepatocytes exposed to , where accumulation and activation correlate with DNA fragmentation and cell viability loss. In high-dose scenarios, energy failure from prolonged transcriptional blockade shifts toward , characterized by ATP depletion and membrane rupture in affected cells. Organ-specific effects manifest prominently in the liver, where RNAP II-rich hepatocytes undergo , leading to centrilobular and elevated transaminases within 24 hours in rat models. Kidneys experience secondary tubular damage, primarily from toxin reabsorption and hepatic failure-induced hypoperfusion. In the , initial damage causes mucosal sloughing and barrier disruption, exacerbating fluid loss. The dose-response exhibits a low threshold for toxicity, approximately 0.1 mg/kg in sensitive species like dogs, with effects scaling to selective impairment in proliferating cells that demand high transcriptional activity. In rat models, liver enzyme activities, such as , can rise dramatically—indicating severe damage—within 24 hours post-exposure, reflecting an 80% or greater reduction in functional capacity. Systemically, gastrointestinal losses from mucosal injury induce and imbalances, while precipitates through depleted synthesis of clotting factors. Notably, amatoxins lack direct neurotoxic effects, with involvement arising secondarily from metabolic derangements.

Clinical Manifestations

Symptoms and Progression

Amatoxin poisoning in humans typically unfolds in distinct phases following ingestion, beginning with a latent period of 6 to 12 hours during which individuals remain asymptomatic, often leading to delayed medical seeking. This is followed by the gastrointestinal phase from 12 to 24 hours post-ingestion, characterized by severe vomiting, profuse watery diarrhea, and intense abdominal pain, which can result in significant dehydration and electrolyte imbalances. An apparent recovery phase may occur around 24 to 48 hours, but the subsequent hepatic phase emerges 2 to 3 days after ingestion, marked by jaundice, markedly elevated liver enzymes such as ALT and AST exceeding 1000 U/L, and oliguria indicating renal involvement. Beyond 3 to 7 days, progression may lead to recovery in milder cases or escalate to multiorgan failure, including hepatic encephalopathy and potential death. The severity of amatoxin poisoning is highly dose-dependent, with a lethal dose estimated at 0.1 mg/kg body weight, and ingestion of as little as one-half to one cap of fresh Amanita phalloides (approximately 10-20 g), which may contain 2-10 mg of amatoxin, sufficient to cause fatal outcomes in adults. A hallmark of amatoxin poisoning is the deceptive nature of its initial symptoms, which may appear mild or resolve temporarily, masking the underlying lethality; untreated mortality rates range from 10% to 50%, though rare neurological effects such as seizures can occur in severe cases due to hepatic complications. Epidemiologically, amatoxin poisonings account for approximately 100-200 cases annually in the United States and combined as of 2015, with higher incidence in regions where wild foraging is common; as of 2023, cases remain rare in the US (∼50/year) but increasing in due to trends, and children are particularly vulnerable due to their lower body weight, resulting in proportionally higher toxin exposure per kilogram. Notable historical clusters include a 1997 incident in involving misidentified mushrooms, which highlighted risks associated with and led to nine hospitalizations and two deaths from amatoxin exposure.

Pathophysiology

Amatoxins, primarily , exert their hepatotoxic effects by binding to and inhibiting , which halts mRNA transcription and disrupts protein synthesis in hepatocytes, leading to nucleolar disintegration and centrilobular . This initial cellular disruption progresses to a broader inflammatory response, including a characterized by elevated tumor necrosis factor-alpha (TNF-α) levels that sensitize hepatocytes to and amplify . Concurrently, arises from increased (ROS) production and , further exacerbating mitochondrial dysfunction and apoptotic pathways via upregulation of , Bax, and activation. These mechanisms culminate in fulminant hepatic failure, marked by severe with international normalized ratio (INR) values exceeding 6, profound elevation, and potential progression to multi-organ dysfunction within 3–7 days post-ingestion. Renal involvement in amatoxin poisoning manifests as , driven by splanchnic vasodilation-induced renal and direct toxin accumulation in the kidneys, where amatoxin concentrations can reach 60–90 times those in the liver due to tubular reabsorption. Hypoperfusion secondary to hepatic failure contributes to (), compounding renal impairment and accelerating the decline in . In the , amatoxins induce through similar inhibition, compromising the and promoting bacterial translocation, which may initiate and sepsis-like states. Prognostic factors include serum amatoxin levels, which correlate with the severity of ; peak exceeding 6 mg/dL (approximately 103 μmol/L) signals a poor outcome, often necessitating . Co-ingested nutrients can modulate toxin absorption by altering gastric emptying and enterohepatic recirculation, potentially influencing the dose-dependent progression of systemic toxicity. Rodent models of amatoxin poisoning closely parallel human disease, demonstrating 50–60% hepatocyte necrosis by day 3 in mice, driven by transcription arrest and inflammatory cascades, akin to the centrilobular-to-panlobular hepatic damage observed in human autopsies and biopsies.

Diagnosis and Detection

Clinical Assessment

The clinical assessment of suspected amatoxin poisoning begins with a thorough history to establish potential exposure. Clinicians should inquire about recent mushroom foraging, identification of consumed species, details of shared meals involving wild mushrooms, and the precise timing of ingestion, as the toxin typically manifests after a latent period of 6 to 12 hours (range 6 to 48 hours). Risk factors such as pediatric or elderly age, which increase toxin absorption and morbidity, should also be noted during this evaluation. Physical examination emphasizes early detection of gastrointestinal effects and systemic involvement. Signs of , including dry mucous membranes, , and , are common during the initial phase, alongside abdominal tenderness from severe . Vital signs must be closely monitored for , while later assessments may reveal early or hepatic tenderness as liver involvement progresses. Differential diagnosis requires distinguishing amatoxin poisoning from other conditions with overlapping features. Unlike muscarine-containing mushroom toxicity, which causes immediate symptoms such as salivation, lacrimation, and , amatoxin presents with delayed onset. It must also be differentiated from , which lacks the prominent initial phase, and acute foodborne illnesses like bacterial , characterized by shorter incubation periods of hours rather than days. Prognostic evaluation utilizes the adapted for non-acetaminophen-induced , which predict poor outcomes and potential need for transplantation. Criteria include greater than 100 seconds (equivalent to INR >6.5), or any three of the following: greater than 50 seconds (INR >3.5), serum bilirubin greater than 300 μmol/L (17.5 mg/dL), patient age less than 10 years or greater than 40 years, or time from onset of to development of greater than 7 days. Initial case management follows established protocols, including immediate notification to regional poison control centers for expert guidance and reporting to public health authorities such as the CDC, particularly for suspected outbreaks or severe cases to facilitate and response. confirmation of amatoxins in or serum can support the clinical suspicion but is not required for initial assessment.

Laboratory Methods

Laboratory detection of amatoxins primarily involves analyzing biological samples such as , serum, and gastric contents, with being the preferred matrix due to higher toxin concentrations and longer detectability compared to serum or plasma. These samples are ideally collected within 36 hours post-exposure, as amatoxins in serum typically remain detectable for about 30 hours, while may show presence up to 72 hours or longer in some cases. Gastric contents are useful in early presentations, allowing detection as soon as 90-120 minutes after ingestion. Chromatographic techniques, particularly high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS), serve as the gold standard for quantitative amatoxin analysis due to their high sensitivity and specificity. This method achieves limits of detection (LOD) around 1 ng/mL in urine and serum, using C18 columns where alpha-amanitin typically elutes with a retention time of approximately 8 minutes under optimized conditions. Sample preparation often involves solid-phase extraction to minimize matrix effects, enabling accurate quantification of alpha-, beta-, and gamma-amanitin isoforms. Immunoassays, such as enzyme-linked immunosorbent assay () kits, provide a faster alternative for initial screening, relying on monoclonal antibodies that target the characteristic bicyclic octapeptide ring structure of amatoxins. These assays offer sensitivities in the range of 5-10 ng/mL, with cut-off values often set at 10 ng/mL for clinical decision-making in urine samples. While less specific than chromatographic methods, are widely used in diagnostic laboratories for their simplicity and ability to process multiple samples rapidly. Histological examination of liver biopsies, if performed, may reveal centrilobular , apoptosis, and with minimal , supporting amatoxin-induced . However, this finding is non-specific, as similar patterns occur in various hepatotoxic conditions including alcoholic and non-alcoholic , limiting its diagnostic utility without corroborative biochemical evidence. Recent advances include point-of-care rapid tests like lateral flow immunoassays (LFIA) developed in the , which enable on-site detection in urine with visual readouts in under 10 minutes and specificities exceeding 95%. These assays achieve LODs of approximately 0.3 ng/mL for alpha-amanitin, facilitating timely in suspected poisonings. In forensic contexts, such as autopsies, HPLC-MS/MS remains essential for confirming amatoxin presence in postmortem urine, blood, or tissues, aiding in cause-of-death determinations.

Treatment and Management

Supportive Therapies

Supportive therapies form the cornerstone of managing amatoxin poisoning, focusing on mitigating complications from gastrointestinal losses, hepatic injury, and potential multiorgan failure. Initial fluid and electrolyte management is critical to counteract dehydration and electrolyte imbalances resulting from profuse vomiting and diarrhea. Intravenous hydration with isotonic fluids, such as 0.9% sodium chloride, is administered aggressively, typically 3-6 liters in adults over the first 24 hours, to maintain urine output at 2-3 mL/kg/hour and prevent acute kidney injury. Close monitoring for hyponatremia and other imbalances, such as hypokalemia, is essential, with serial electrolyte panels guiding adjustments to avoid cerebral edema in the context of evolving hepatic dysfunction. Gastrointestinal decontamination aims to limit toxin absorption and interrupt enterohepatic recirculation. Activated charcoal is recommended at a dose of 1 g/kg orally or via nasogastric tube, ideally within 1-2 hours of , though it may be beneficial up to 12 hours if no contraindications exist. Multiple doses, such as every 4-6 hours for 24-48 hours if tolerated, enhance elimination by binding amatoxins in the gut. Emetics should be avoided due to the risk of aspiration and further gastrointestinal irritation. Organ support is tailored to emerging complications, particularly in cases progressing to acute liver or kidney failure. is indicated for renal failure to manage and fluid overload, though it does not effectively remove amatoxins from the bloodstream due to their intracellular binding. is employed for patients developing with respiratory compromise or aspiration risk, often requiring endotracheal for airway protection. Nutritional support via total is initiated if enteral feeding is not feasible, providing calories, glucose, and branched-chain to prevent while minimizing hepatic stress. Monitoring protocols are intensive to detect deterioration early. Serial liver function tests, including (ALT), aspartate aminotransferase (AST), , and , along with coagulation panels (/international normalized ratio), are performed every 12 hours to track hepatic injury progression. Criteria for intensive care unit transfer include rapidly rising ALT levels exceeding 2000 U/L, coagulopathy with INR greater than 2, or signs of , ensuring prompt escalation of care. Aggressive supportive care has significantly improved outcomes, with meta-analyses and retrospective reviews indicating a reduction in mortality from approximately 50% in the pre-modern era to less than 10% currently.

Antidotal Interventions

Silibinin, the primary active component of silymarin derived from milk thistle (), is administered intravenously at doses of 20-50 mg/kg/day to treat amatoxin . It competitively inhibits the uptake of amatoxins into hepatocytes by binding to the organic anion-transporting polypeptide 1B3 (OATP1B3) transporter and also blocks toxin secretion into . Evidence from German clinical studies in the 1980s demonstrated that this intervention reduced mortality rates to approximately 10% in patients with confirmed intoxication when initiated early. High-dose penicillin G is another established antidotal , typically given at 250,000-1,000,000 IU/kg/day via continuous intravenous . The proposed mechanism involves inhibition of amatoxin penetration into hepatocytes, though the exact pathway remains unclear. While randomized controlled trials are lacking, retrospective analyses and clinical guidelines support its use due to observed reductions in hepatic injury severity, with recommendations emphasizing administration alongside for synergistic effects. In cases of fulminant hepatic failure induced by amatoxins, orthotopic represents the definitive intervention, particularly when the (MELD) score exceeds 30. Survival rates post-transplantation approach 70-75%, but success depends on rapid evaluation and transplantation ideally within 48 hours of symptom onset to minimize multi-organ failure. Prognostic models incorporating factors like and levels guide candidacy, with timely referral to transplant centers critical for outcomes. Emerging antidotal strategies include N-acetylcysteine (NAC), administered off-label at standard acetaminophen overdose protocols (e.g., 150 mg/kg followed by 12.5 mg/kg/h infusion) to counteract and support replenishment in amatoxin-damaged hepatocytes. Systematic reviews indicate potential benefits when combined with primary therapies, though evidence remains inconclusive from observational data. Corticosteroids are contraindicated in amatoxin due to heightened risk in the context of and , as per guidelines for managing fulminant hepatic injury.

Research Developments

Historical Discoveries

The toxicity of Amanita phalloides, the primary source of amatoxins, has been recognized since ancient times, with historical accounts suggesting it may have caused the death of Roman Emperor Claudius in AD 54 and Holy Roman Emperor Charles VI in 1740. The species was formally described in the late 18th century by French mycologist Jean Baptiste François Bulliard, who illustrated it under the name Agaric bulbeux in his Herbier de la France (1780–1781), highlighting its phallic shape and deadly nature based on contemporary observations of poisoning symptoms. Early scientific investigations into its poisons began in the 19th century, with German pharmacologist Rudolf Kobert isolating crude hemolytic extracts from A. phalloides in 1891, naming the thermostable component phallin and demonstrating its blood-dissolving effects in animal models, though this was later distinguished from the primary amatoxins. Significant advances in purification occurred in the mid-20th century through the work of Heinrich Otto Wieland, a Nobel laureate (1927) for his studies on bile acids and , whose laboratory at the University of systematically fractionated A. phalloides toxins. In 1941, Wieland and Rudolf Hallermayer successfully isolated and crystallized , the most potent amatoxin, as a stable, heat-resistant responsible for the mushroom's , building on earlier partial separations and confirming its role via intravenous injections in mice and rabbits. This breakthrough shifted focus from unstable hemolysins like phallin to the bicyclic octapeptides, enabling quantitative toxicity assessments; animal studies in the and established LD50 values, such as 0.2–0.3 mg/kg for in mice via intraperitoneal administration, underscoring its extreme potency compared to other natural toxins. The molecular mechanism of amatoxin toxicity was elucidated in the late 1960s using cell-free systems and models. Italian biochemists F. Stirpe and L. Fiume first reported in 1967 that potently inhibits RNA synthesis in mouse liver nuclei, reducing incorporation of into by over 90% at low doses, linking this to rapid hepatic observed in poisonings. Building on this, a 1970 study by T.J. Lindell and colleagues identified the specific target as (RNAP II), the nucleoplasmic enzyme responsible for mRNA transcription, with binding irreversibly at nanomolar concentrations in purified calf thymus extracts, halting eukaryotic protein synthesis without affecting RNAP I or III. These findings explained the delayed onset of symptoms in human cases, as reported in European medical literature during the 1950s, including outbreaks in and where clusters of 4–10 victims per incident highlighted the toxin's enterohepatic recirculation and liver . Pioneering detection methods emerged in the 1970s to aid clinical diagnosis amid rising awareness of amatoxin poisonings. Thin-layer chromatography (TLC) was introduced for separating and visualizing amatoxins in mushroom extracts and biological fluids, with early protocols using silica gel plates and UV detection achieving limits of 1–5 μg per sample, as developed in Wieland's group for routine forensic use. Concurrently, radioimmunoassay (RIA) techniques were adapted for amatoxin quantification, offering higher sensitivity (down to 0.1 ng/mL in urine) through antibody-based detection of α- and β-amanitin, first validated in poisoned patient samples to confirm exposure within 24–48 hours post-ingestion. These methods marked a shift from symptomatic diagnosis to toxin-specific confirmation, informing the first systematic reviews of European cases.

Contemporary Studies

In the genomic era of the 2010s, sequencing efforts for Amanita species revealed key biosynthetic pathways for amatoxins, identifying ribosomal peptide-encoding genes such as AMA1 and the MSDIN gene family, which are clustered and taxonomically restricted to toxin-producing fungi. These discoveries, including the 2022 analysis of multiple Amanita genomes alongside those of Lepiota and Galerina, demonstrated that the α-amanitin-encoding gene is conserved across amatoxin-producing lineages, enabling evolutionary tracing of toxin production mechanisms. Such genomic insights have facilitated targeted studies on toxin gene expression, with differential regulation observed in fruiting bodies versus vegetative tissues. Recent therapeutic research has explored antidotes beyond traditional supportive care, with a 2023 high-throughput screen identifying STT3B as essential for toxicity in human cells, leading to the repurposing of as a specific inhibitor that blocks toxin entry and reduces lethality in preclinical models. For established treatments like , innovations in delivery systems include formulations to enhance and targeted liver uptake, potentially improving efficacy against amatoxin-induced hepatic damage, as demonstrated in and animal studies focused on sustained release profiles. A 2025 multi-center study (Amanita-PEX) analyzed therapeutic plasma exchange in amatoxin-associated from 2013 to 2024, providing new insights into extracorporeal therapies. Epidemiological data from the 2020s indicate a rise in amatoxin poisoning incidents linked to climate-driven expansions in the range of toxic species, such as , with modeled increases in climatic suitability projected to affect up to 70% of indigenous communities in regions like by mid-century. In and , warmer temperatures and altered patterns have correlated with earlier seasonal occurrences and higher hospitalization rates, though no significant shift in poisoning timing was observed in South-Eastern from 2005 to 2023. Global estimates suggest approximately 10,000 illnesses and 100 deaths annually from poisonings, predominantly amatoxin-related, underscoring the need for enhanced surveillance. In Türkiye, a 2024 nationwide cohort analysis of over 1,000 cases highlighted seasonal peaks in spring and autumn, attributing variability to climatic trends like prolonged wet periods. Beyond toxicology, amatoxins have been repurposed as potent inhibitors in , conjugated to antibodies for targeted delivery to tumor cells via antibody-drug conjugates (ADCs). Heidelberg Pharma's HDP-101, an anti-BCMA amanitin-based ADC, advanced to Phase I/IIa trials by 2024 and in 2025 received FDA Fast Track designation, demonstrating safety and preliminary efficacy in relapsed/refractory patients, with amanitin inducing in both proliferating and quiescent cells. Similarly, anti-CD37 α-amanitin conjugates showed antitumor activity in preclinical B-cell malignancy models, supporting clinical translation due to the payload's and low . Additionally, novel amanitin-based ADCs targeting TROP2 have shown promising preclinical results for treatment as of 2025. These developments highlight amatoxins' high when site-specifically linked, with ongoing trials emphasizing their role in overcoming resistance in solid and hematologic cancers.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK431052/
  2. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/amatoxin
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC11333700/
  4. https://pubchem.ncbi.nlm.nih.gov/compound/Alpha-Amanitin
  5. https://www.mdpi.com/1420-3049/28/15/5932
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC10421264/
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC7076753/
  8. https://pubchem.ncbi.nlm.nih.gov/compound/gamma-Amanitin
  9. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/phallotoxin
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC3511042/
  11. https://www.hilarispublisher.com/open-access/deactivation-study-of-amanitin-toxicity-in-poisonous-amanita-sppmushrooms-by-the-common-substances-in-vitro-2157-7145-1000396.pdf
  12. https://www.tandfonline.com/doi/full/10.3852/09-131
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC9171917/
  14. https://escholarship.org/content/qt4zp4b2j7/qt4zp4b2j7_noSplash_efe1463c9516793ad872c0ac9f9c8c4a.pdf
  15. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0246575
  16. https://koreascience.kr/article/JAKO202020550933066.pdf
  17. https://www.mykoweb.com/TFWNA/P-14.html
  18. http://pringlelab.botany.wisc.edu/pubs/Pringle_MolEcol_2009.pdf
  19. https://www.pnas.org/doi/10.1073/pnas.0707340104
  20. https://www.researchgate.net/publication/325054127_Biosynthesis_of_the_Amanita_Cyclic_Peptide_Toxins
  21. https://imafungus.biomedcentral.com/articles/10.5598/imafungus.2018.09.02.01
  22. https://link.springer.com/article/10.1007/BF01913234
  23. https://www.science.org/doi/10.1126/science.170.3956.447
  24. https://pubmed.ncbi.nlm.nih.gov/1286940/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC146057/
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC8230822/
  27. https://www.sciencedirect.com/science/article/abs/pii/S0196978120300632
  28. https://pubmed.ncbi.nlm.nih.gov/32387737/
  29. https://pubmed.ncbi.nlm.nih.gov/20207116/
  30. https://journals.sagepub.com/doi/pdf/10.1177/0960327107083972
  31. https://www.zora.uzh.ch/server/api/core/bitstreams/6b3ecc85-4933-4d37-99fb-563103735227/content
  32. https://www.sciencedirect.com/science/article/abs/pii/S0041010110000449
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC5679676/
  34. https://www.cdc.gov/mmwr/volumes/66/wr/mm6621a1.htm
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC4863189/
  36. https://www.sciencedirect.com/science/article/pii/S0731708523001905
  37. https://www.cdc.gov/mmwr/preview/mmwrhtml/00047808.htm
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC7868946/
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC4057534/
  40. https://pubmed.ncbi.nlm.nih.gov/9041255/
  41. https://www.mdpi.com/1422-0067/25/23/13028
  42. https://www.journal-of-hepatology.eu/article/S0168-8278(04)00600-2/fulltext
  43. https://emedicine.medscape.com/article/167398-clinical
  44. https://www.ncbi.nlm.nih.gov/books/NBK537111/
  45. https://wikem.org/wiki/Amanita_mushrooms
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC3395149/
  47. https://www.journal-of-hepatology.eu/article/S0168-8278%2806%2900615-5/fulltext
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC4885043/
  49. https://pubmed.ncbi.nlm.nih.gov/3813886/
  50. https://www.academia.edu/28595850/DETERMINATION_OF_MUSHROOM_TOXIN_ALPHA_AMANITIN_IN_SERUM_BY_LIQUID_CHROMATOGRAPHY_MASS_SPECTROMETRY_AFTER_SOLID_PHASE_EXTRACTION
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC6950293/
  52. https://www.pathologyoutlines.com/topic/liverpatternshepaticinjury.html
  53. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0231781
  54. https://academic.oup.com/jat/advance-article/doi/10.1093/jat/bkaf018/8123743
  55. https://www.ontariopoisoncentre.ca/siteassets/pdfs/english/protocols/amatoxin_revised-july-2022.pdf
  56. https://emedicine.medscape.com/article/167398-treatment
  57. https://pubmed.ncbi.nlm.nih.gov/31127688/
  58. https://www.researchgate.net/publication/16335483_Chemotherapy_of_Amanita_phalloides_Poisoning_with_Intravenous_Silibinin
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC3414726/
  60. https://onlinelibrary.wiley.com/doi/10.5402/2012/190869
  61. https://www.tandfonline.com/doi/full/10.1080/15563650.2022.2098139
  62. https://annalsoftransplantation.com/abstract/full/idArt/946485
  63. https://pubmed.ncbi.nlm.nih.gov/32609548/
  64. https://www.aasld.org/sites/default/files/2023-03/Acute%2520Liver%2520Failure%2520Update2011.pdf
  65. http://www.tullabs.com/amanita/?Amanita%20phalloides
  66. https://link.springer.com/chapter/10.1007/978-3-642-71295-1_5
  67. https://link.springer.com/content/pdf/10.1007/978-3-642-71295-1.pdf
  68. https://portlandpress.com/biochemj/article/105/2/779/3410/Studies-on-the-pathogenesis-of-liver-necrosis-by
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC3008271/
  70. https://www.pnas.org/doi/10.1073/pnas.2201113119
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC8156247/
  72. https://www.nature.com/articles/s41467-023-37714-3
  73. https://www.tandfonline.com/doi/full/10.2147/DDDT.S483140
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC12573913/
  75. https://www.revistascca.unam.mx/atm/index.php/atm/article/view/53244
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC11653814/
  77. https://www.npr.org/sections/goatsandsoda/2023/05/17/1175494500/new-hope-for-an-antidote-to-death-cap-mushrooms-and-other-poison-fungi
  78. https://www.turkjgastroenterol.org/Content/files/sayilar/417/TJG_20240368_nlm_new_indd.pdf
  79. https://aacrjournals.org/mct/article/20/2/367/274590/HDP-101-an-Anti-BCMA-Antibody-Drug-Conjugate
  80. https://www.cancernetwork.com/view/hdp-101-receives-fda-fast-track-designation-in-multiple-myeloma
  81. https://ashpublications.org/blood/article/144/Supplement%201/3381/532944/The-Anti-BCMA-Antibody-Drug-Conjugate-Hdp-101-with
  82. https://ashpublications.org/blood/article/140/13/1565/486081/Anti-CD37-amanitin-conjugated-antibodies-as
  83. https://aacrjournals.org/mct/article-pdf/24/4/485/3560494/mct-24-0266.pdf
  84. https://www.sciencedirect.com/science/article/abs/pii/S1740674918300350
Add your contribution
Related Hubs
User Avatar
No comments yet.